Literature DB >> 11064383

Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.

S Pham1, T S Wiedmann.   

Abstract

The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments. Powder x-ray diffraction, differential scanning calorimetry, differential thermal analysis, and scanning electron microscopy were used to characterize the aerosol particles and starting material. No change in phase was detected, although the aerosol particles appeared to contain residual solvent. The dissolution rate of the aerosol particles in saline was low and variable. Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies. Survanta also increased rate of dissolution, in a manner similar to sodium dodecyl sulfate. Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. These results show that lung surfactant has the potential of enhancing the rate and extent of dissolution of drugs administered to the lung. Copyright 2001 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 90: 98-104, 2001

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11064383     DOI: 10.1002/1520-6017(200101)90:1<98::aid-jps11>3.0.co;2-5

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  12 in total

1.  Solid lipid budesonide microparticles for controlled release inhalation therapy.

Authors:  Matteo Mezzena; Santo Scalia; Paul M Young; Daniela Traini
Journal:  AAPS J       Date:  2009-11-12       Impact factor: 4.009

2.  Applicability of an ultrasonic nebulization system for the airways delivery of beclomethasone dipropionate in a murine model of asthma.

Authors:  Boska Hrvacić; Berislav Bosnjak; Marijan Tudja; Milan Mesić; Mladen Merćep
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

3.  Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent.

Authors:  Nashwa El-Gendy; Kristin L Aillon; Cory Berkland
Journal:  Int J Pharm       Date:  2010-03-07       Impact factor: 5.875

4.  Iodinated NanoClusters as an inhaled computed tomography contrast agent for lung visualization.

Authors:  Kristin L Aillon; Nashwa El-Gendy; Connor Dennis; Jeffrey P Norenberg; Jacob McDonald; Cory Berkland
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

5.  Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols.

Authors:  Nashwa El-Gendy; Warangkana Pornputtapitak; Cory Berkland
Journal:  Eur J Pharm Sci       Date:  2011-09-21       Impact factor: 4.384

6.  Solubilization of cationic drugs in lung surfactant.

Authors:  Xiangmin Liao; Timothy S Wiedmann
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

7.  Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution.

Authors:  Nashwa El-Gendy; Eric M Gorman; Eric J Munson; Cory Berkland
Journal:  J Pharm Sci       Date:  2009-08       Impact factor: 3.534

8.  Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration.

Authors:  Nashwa El-Gendy; Cory Berkland
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

9.  New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis.

Authors:  Christophe Duret; Nathalie Wauthoz; Thami Sebti; Francis Vanderbist; Karim Amighi
Journal:  Int J Nanomedicine       Date:  2012-10-18

10.  A Biocompatible Synthetic Lung Fluid Based on Human Respiratory Tract Lining Fluid Composition.

Authors:  Abhinav Kumar; Wachirun Terakosolphan; Mireille Hassoun; Kalliopi-Kelli Vandera; Astrid Novicky; Richard Harvey; Paul G Royall; Elif Melis Bicer; Jonny Eriksson; Katarina Edwards; Dirk Valkenborg; Inge Nelissen; Dave Hassall; Ian S Mudway; Ben Forbes
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.